跳转至内容
Merck
CN

17850

环丙沙星

≥98% (HPLC)

别名:

1-环丙基-6-氟-4-氧代-7(1-哌嗪基)-1,4-二氢喹啉-3-羧酸, 西普乐

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C17H18FN3O3
化学文摘社编号:
分子量:
331.34
UNSPSC Code:
41116105
NACRES:
NA.21
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
3568352
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

环丙沙星, ≥98% (HPLC)

InChI

1S/C17H18FN3O3/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h7-10,19H,1-6H2,(H,23,24)

SMILES string

OC(=O)C1=CN(C2CC2)c3cc(N4CCNCC4)c(F)cc3C1=O

InChI key

MYSWGUAQZAJSOK-UHFFFAOYSA-N

agency

EPA 1694

assay

≥98% (HPLC)

form

powder or crystals

antibiotic activity spectrum

Gram-negative bacteria
Gram-positive bacteria

application(s)

environmental

mode of action

DNA synthesis | interferes
enzyme | inhibits

Quality Level

Gene Information

正在寻找类似产品? 访问 产品对比指南

Application

环丙沙星在临床中广泛用于对付革兰阳性和阴性菌,治疗皮肤、眼睛、泌尿道、下呼吸道、胃肠道等多个部位的感染。 还可联合多种抗菌药物对抗细菌生物膜和多重耐药微生物。另外,开发的衍生物可合成新型抗菌药物,疗效增强且具有抗菌、抗真菌、抗HIV、抗肿瘤和抗TB等各种抗微生物活性。

Biochem/physiol Actions

环丙沙星的作用机制是 通过抑制DNA促旋酶(gyrase)和影响细菌细胞壁来抑制细菌DNA合成 。

General description

环丙沙星是第二代广谱氟喹诺酮抗生素,具有广泛抗菌性和药动学特征,广泛用于对抗细菌感染。化学名称是1-环丙基-6-氟-4-氧代-7-(哌嗪-1-基)-1,4-二氢喹啉-3-羧酸。

化学结构:氟喹诺酮

存储类别

11 - Combustible Solids

wgk

WGK 2

ppe

Eyeshields, Gloves, type N95 (US)


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

  1. Which document(s) contains shelf-life or expiration date information for a given product?

    If available for a given product, the recommended re-test date or the expiration date can be found on the Certificate of Analysis.

  2. How do I get lot-specific information or a Certificate of Analysis?

    The lot specific COA document can be found by entering the lot number above under the "Documents" section.

  3. What is the solubility of Product 17850, Ciprofloxacin?

    17850 is the free base of ciprofloxacin. It is soluble in 0.1N HCl at 25 mg/ml.  Ciprofloxacin is poorly soluble in DMSO. For HPLC, dissolve the sample material in a mixture ofAcetonitril/Phosphoric acid pH 2.4 by ultrasonification (5 mg/10 ml solvent).

  4. Can Product 17850, Ciprofloxacin, be used in cell culture?

    We have not done cell culture testing with this product.

  5. What is the potency of Product 17850, Ciprofloxacin?

    The potency of this product has not been determined by our Quality Control or by our supplier.

  6. Can Product 17850, Ciprofloxacin, be used to remove Mycoplasma contaminations?

    We have not tested the product for that application. However, there is a reference in Roche's Biochemica Newsletter Issue 1 from 1996 that describes using Ciprofloxacin in mycoplasma contamination.

  7. How do I find price and availability?

    There are several ways to find pricing and availability for our products. Once you log onto our website, you will find the price and availability displayed on the product detail page. You can contact any of our Customer Sales and Service offices to receive a quote.  USA customers:  1-800-325-3010 or view local office numbers.

  8. What is the Department of Transportation shipping information for this product?

    Transportation information can be found in Section 14 of the product's (M)SDS.To access the shipping information for this material, use the link on the product detail page for the product. 

  9. My question is not addressed here, how can I contact Technical Service for assistance?

    Ask a Scientist here.

Gui-Fu Zhang et al.
European journal of medicinal chemistry, 146, 599-612 (2018-02-07)
Bacterial infections represent a significant health threat globally, and are responsible for the majority of hospital-acquired infections, leading to extensive mortality and burden on global healthcare systems. The second generation fluoroquinolone ciprofloxacin which exhibits excellent antimicrobial activity and pharmacokinetic properties
The resistance mechanisms of bacteria against ciprofloxacin and new approaches for enhancing the efficacy of this antibiotic
Shariati et al.
Frontiers in public health, 10 (2022)
Orjan Samuelsen et al.
Antimicrobial agents and chemotherapy, 54(1), 346-352 (2009-11-04)
Scandinavia is considered a region with a low prevalence of antimicrobial resistance. However, the number of multidrug-resistant (MDR) Gram-negative bacteria is increasing, including metallo-beta-lactamase (MBL)-producing Pseudomonas aeruginosa. In this study MBL-producing P. aeruginosa isolates identified in Norway (n = 4)
Athina Andrea et al.
Microorganisms, 7(3) (2019-03-22)
Among non-mammalian infection model organisms, the larvae of the greater wax moth Galleria mellonella have seen increasing popularity in recent years. Unlike other invertebrate models, these larvae can be incubated at 37 °C and can be dosed relatively precisely. Despite
Gisele Peirano et al.
Antimicrobial agents and chemotherapy, 54(3), 1327-1330 (2010-01-06)
Phenotypic and genotypic methods were used to characterize extended-spectrum-beta-lactamase (ESBL)-producing Escherichia coli isolated in 2007 from 11 different Canadian medical centers. Of the 209 ESBL-producing E. coli isolates tested, 148 (71%) produced CTX-M-15, 17 (8%) produced CTX-M-14, 5 (2%) produced

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持